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Blockade  of immune  checkpoints  has emerged  as  key  strategy  in the  development  of effective  cancer
therapies.  In  contrast  to cell  surface  checkpoints  like  CTLA-4  and  PD-1,  however,  additional  cancer  ther-
apeutic  targets  are  located  inside  the effector  immune  cells.  Targeting  these  alternative  checkpoints  in
cancer  immunotherapy  with  the  goal  to  strengthen  the  patient’s  immune  system  are  likely to  extend
the  beneﬁts  of  cancer  immunotherapy  in the  near  future.  Along  this  line,  we have  deﬁned  and  validated
the  orphan  nuclear  receptor  NR2F6  (nuclear  receptor  subfamily  2 group  F  member  6, also  called  Ear-2)
as  an  intracellular  immune  checkpoint  in  effector  T cells.  NR2F6  acts  as a novel  master  switch  of antitu-
mor  responses  against  both  transplantable  and  spontaneous  tumors  in  mice  relevant  for human  cancer.
NR2F6  directly  represses  transcription  of  key cytokine  genes  in  T  effector  cells  relevant  for  tumor  cellheckpoint rejection,  such  as  IL-2, IFN  and  TNF. Thus,  in  the  presence  of  NR2F6,  T cell  activation  is limited  within
the  tumor  microenvironment.  This  deﬁnes  NR2F6  as  a key  checkpoint  governing  the  amplitude  of  cancer
immune  surveillance.  Based  on our study,  an approach  shall  be  initiated  to identify  low  molecular  weight
compounds  that selectively  interfere  with  NR2F6  function  in  the  clinic.
©  2016  The  Authors.  Published  by Elsevier  B.V.  on behalf  of  European  Federation  of Immunological
Societies.  This  is an  open  access  article  under  the CC  BY license  (http://creativecommons.org/licenses/. Introduction
Cancer is a severe health problem with increasing prevalence in
rst world countries. Cancer comprises multi-factorial disorders,
nd due to the complexity of the disease, a mechanistic under-
tanding of the numerous acquired hallmarks of cancer is limited.
owever, malfunction of cancer immune surveillance is emerging
s a crucial event in cancer etiology. Historically, in the late nine-
eenth century, William B. Coley made a pioneering observation of
umor shrinkage and disappearance following injection of bacterial
roducts in and around tumors. Paul Ehrlich suggested the crosstalk
etween the immune system and cancer in 1909; a half century
ater, Burnet and Thomas formulated the cancer immune surveil-
ance hypothesis [1]. Due to the absence of sufﬁcient experimental
Abbreviations: AP-1, activation protein 1; CTLA-4, cytotoxic T lymphocyte-
ssociated protein-4; GM-CSF, granulocyte-macrophage colony-stimulating factor;
L-2, interleukin 2; IFN , interferon ; NFAT, nuclear factor of activated T cells;
R2F6, nuclear receptor subfamily 2, group F, member 6 - alias: Ear2/COUP-TFIII;
D-1/PD-L1, programmed cell death-1 and its ligand-1; PKC, protein kinase C; RORC,
etinoid-related orphan receptor – alias: ROR t or NR1F3; TCR, T cell receptor; TIL,
umor inﬁltrating lymphocyte; TNF, tumor necrosis factor .
∗ Corresponding author.
E-mail address: gottfried.baier@i-med.ac.at (G. Baier).
ttp://dx.doi.org/10.1016/j.imlet.2016.03.007
165-2478/© 2016 The Authors. Published by Elsevier B.V. on behalf of European Federati
http://creativecommons.org/licenses/by/4.0/).by/4.0/).
evidence, however, this hypothesis had to be abandoned shortly
thereafter. Today’s reﬁned technologies including mouse models
of cancer immunity have validated the key importance of immu-
nity in cancer progression. It is well established that mice who lack
essential components of the innate or adaptive immune system
(e.g. Rag1-deﬁcient mice) are signiﬁcantly more susceptible to the
development of spontaneous or chemically induced tumors. Con-
sistently, the immune system of transplant patients who receive
immunosuppressive drugs is less able to detect and destroy cancer
cells [2].
The immune system has been demonstrated to serve key roles
in the prevention of tumors. It can protect the host from virus-
induced tumors by eliminating or suppressing viral infections.
The timely elimination of pathogens and prompt resolution of
inﬂammation can prevent the establishment of an inﬂamma-
tory environment known to promote tumorigenesis. Finally, the
immune system can speciﬁcally identify and eliminate tumor cells
on the basis of tumor-speciﬁc antigens or molecules induced by
cellular stress, a phenomenon called tumor immune surveillance
[3]. However, immune surveillance represents only one dimen-
sion of the complex interplay between the immune system and
cancer. New results demonstrate that the immune system also
promotes the emergence of tumors with reduced immunogenic-
ity capable of escaping immune recognition and destruction. These
on of Immunological Societies. This is an open access article under the CC BY license
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wo faces of the immune system during tumorigenesis prompted a
eﬁnement of the cancer immune surveillance hypothesis into one
ermed “cancer immunoediting”, encompassing both the potential
ost-protective and the tumor-sculpting functions of the immune
ystem throughout cancer development [4].
. T cell immunology meets oncology
CD8+ cytotoxic T cells recognize and kill tumor cells in an MHC-
estricted and perforin-dependent manner. Mechanistically, tumor
ells and/or tumor antigens are taken up, processed, and cross-
resented to T cells by professional APCs and induce CD8+ T cell
esponses [2,5]. Nevertheless, stimulation via the tumor antigen-
peciﬁc TCR alone is apparently insufﬁcient for activation of naïve
s well as memory CD8+ T cells. Therefore, a co-stimulatory signal
CD28 on the T cell—CD80/CD86 on the APC) is considered essential
or a full activation scenario. This leads to proliferation and differ-
ntiation of naïve CD8+ T cells into effector cytotoxic CD8+ T cells
CTL) and memory CD8+ T cells, resulting in production of cytokines
uch as IFN and the effector molecules perforin and granzyme B,
ediating direct cytolytic activity on the targeted tumor cells [3].
everal groups have shown the critical importance of CD4+ T cells in
he induction and maintenance of antigen-speciﬁc memory CD8+
 cells [6–8]. In the absence of T helper cells, memory CD8+ T cells
xhibit impaired functionality, persistence, and most importantly,
he ability to efﬁciently control a tumor challenge. Especially TH1
ells that secrete high levels of IFN , TNF, and IL-2 cooperate with
he cell-killing functions of CD8+ T cells, and are able to induce up-
egulation of MHCI and MHCII on APCs, thereby strongly enhancing
he duration and magnitude of CTL responses. In detail, the release
f inﬂammatory cytokines such as IL-2 helps to expand the pop-
lation of tumor antigen-speciﬁc CTLs [9]. Additionally, TH1 cells
irectly contribute to antitumor immunity via the release of IFN ,
hereas TNF induces cytotoxic effects independent of B, NK or
D8+ T cells [10,11]. Additionally, activated CD4+ T cells recognize
umor-inﬁltrating macrophages in an MHCII-dependent manner,
onverting IL-10 (interleukin-10)-producing M2  macrophages into
FN -producing M1  macrophages [2]. On the other hand, regulatory
 cells (CD4+CD25+Foxp3+) that normally prevent autoimmunity
y maintaining self-tolerance contribute to immune suppression
y dampening the antitumor immunity caused by CD4+, CD8+ T
ells, DC (dendritic cells) and NK (natural killer) cells at the tumor
ite. Inhibitory cytokines (TGF, IL-10, and IL-35), cytolysis of effec-
or T cells via granzyme-B and perforin, and IL-2 deprivation lead
o Treg-mediated immunosuppression [9]. Moreover, other cells
f the adaptive (TH2, TH17, NKT cells) as well as innate immune
ystem (DC, NK cells, myeloid derived suppressor cells, and tumor-
ssociated macrophages) critically contribute to tumor immune
urveillance.
Consistently, the presence and number of tumor inﬁltrating
ymphocytes (TILs) is a favorable prognostic marker in numerous
ancers. This applies in particular to melanoma, ovarian carcinoma
nd colon carcinoma [12]. The presence of Treg cells in the tumors of
atients with ovarian carcinoma or melanoma, on the other hand, is
 predictor of reduced survival [13,14]. However, the exact molec-
lar mechanisms by which tumors mediate immunosuppression
emain under intense investigation.
. Immunotherapy in cancer
Anticancer treatment, next to basic surgery, is generally catego-
ized into ﬁve different classes: radiation therapy, where deposited
nergy can kill remaining cancer cells or cause genetic changes
esulting in cancer cell death [15]; chemotherapy, which involves
iverse groups of cytotoxic drugs that interfere with cell divisionetters 178 (2016) 31–36
and DNA synthesis [16]; hormonal therapy, where drugs inter-
fere with growth survival signaling through hormone receptors
on cancer cells [17]; targeted therapy, which consists of a novel
group of antibodies or small-molecule kinase inhibitors that specif-
ically target growth signaling pathways in deﬁned cancer; and
immunotherapy, which targets the induction and/or augmentation
of anticancer immune responses [12,18].
Over the past decades, many observations like sponta-
neous remissions, higher cancer incidence in immunosuppressed
patients, tumor-speciﬁc antigens and lymphocytes, gave a strong
push to research in developing efﬁcacious immunotherapy, and
resulted in successful breakthroughs in drug development and
treatment approval against cancer [19]. The advantage of can-
cer immunotherapy is the exquisite power and speciﬁcity of the
immune system in the treatment of malignancy, especially via
the cytotoxic T lymphocyte response. However, because tumors
frequently interfere with effective antitumor immune responses,
immunotherapy has to develop strategies to overcome this hur-
dle [18]. Insights into tumor-speciﬁc immune responses were
obtained in patients with melanoma, since the majority of tumor
immunology studies have been performed on this tumor type.
Although clinical remissions have consistently been observed using
immunotherapies, overall the efﬁcacy remained below a threshold
that justiﬁed their use in the general patient population [19,20].
Nevertheless, there are a few quite distinct strategies that help
boost the immune system against cancer: vaccines, cytokines,
antibodies, immune checkpoint blockade inhibitors, adoptive cell
transfers, and chimeric antigen receptor-modiﬁed T-cell therapy
[12,21].
Few vaccines exist that provide protection from cancer. Either
prophylactic vaccines, such as the quadrivalent HPV vaccine pre-
venting human papilloma virus infection in young girls and boys
[22], or therapeutic vaccines based on antigen-presenting cells,
like dendritic cells, leading to a speciﬁc immune response against
introduced tumor antigens, like sipuleucel-T [23]. The success of
sipuleucel-T has encouraged the development of other therapeutic
prostate cancer vaccines, including the tumor-cell based GVAX-
PCa and the viral vaccine Prostvac [24]. Many vaccine approaches,
including tumor cell vaccines, peptide vaccines, DNA vaccines and
dendritic cell vaccines can induce immune responses, but they have
been basically unsuccessful in achieving any clinical responses [19].
Over the years it has become clear that cancer cells have different
ways of actively suppressing the immune system at the tumor site,
which in fact makes effective vaccinations almost impossible [20].
Cytokines, on the other hand, directly modulate the immune
response and can be used as biological drugs. Two commonly
approved cytokine therapies are IFN against leukemia, sarcoma,
lymphoma, CML  and melanoma [25], and IL-2 against melanoma
and renal cell carcinoma [26]. Cytokine treatment, however, is so
far not a common treatment, except in some adjuvant settings, due
to its high toxicity in patients. The underlying toxicity of IL-2 results
from a capillary leak that leads to ﬂuid extravasation into visceral
organs that can compromise their function, as well as fever, chills,
malaise, and arthralgia [27]. The most common toxicity of sys-
temic administration of type I interferons, namely IFN are fatigue,
anorexia, hepatotoxicity, ﬂu-like symptoms and severe depression
[28].
“Passive” immunotherapy with monoclonal antibodies (mAbs),
raised against speciﬁc antigens, present on tumor cell surfaces, or
directly stimulating the immune response, has outpaced “active”
immunotherapy with antitumor vaccines. Many therapeutic anti-
bodies blocking for example CD20 (ofatumumab, rituximab), EGFR
(trastuzumab, panitumumab, nimotuzumab, cetuximab), and VEGF
(bevacizumab) [20,29] are approved by the FDA. The use of mAbs
as “biologicals” for therapy of cancer became a great success story
of the past decade.
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In contrast to the above-mentioned mAbs targeting mainly
umor cells, immune checkpoint therapies, which target regulatory
athways in immune cells in order to enhance antitumor immune
esponses, have led to even more remarkable clinical advances and
rovided an entirely new handle in the “war against cancer” [30].
he immune system has several checkpoints as a safeguard to keep
tself from attacking normal cells in the body. Cancer cells appar-
ntly take advantage and hitchhike these immune checkpoints to
void being attacked by the immune system [20]. Three immune
heckpoint-blocking agents have now been approved by the FDA
or the treatment of melanoma in the clinic—one antibody against
ytotoxic T-lymphocyte-associated protein 4 (CTLA-4; ipilimumab)
n 2011, and two antibodies against programmed cell death protein
 (PD-1; pembrolizumab and nivolumab) in 2014 [31]. But other
ntibodies, for example those blocking the ligand of programmed
ell death protein 1, PD-L1, or targeting other immune checkpoints
ike surface receptor Tim3, might prove to be successful in the near
uture [32,33].
In detail CTLA-4 is upregulated upon T cell activation, and like
D28, binds B7 molecules with higher afﬁnity, thus leading to
own-regulated T cell activation responses via an ectodomain com-
etition [34]. Thus, blocking its interaction with B7 molecules might
llow T cell responses to persist sufﬁciently to achieve tumor erad-
cation [30]. Unfortunately, however, CTLA-4 blockade has been
ssociated with dramatic autoimmune toxicities as on-target side
ffects, such as colitis, dermatitis, hypophysitis, or pulmonary alve-
litis [12]. PD-1 is also an inhibitory surface receptor upregulated
n activated T cells, as well as on B cells and monocytes. PD-1
as two ligands, PD-L1 (expressed in immune and nonimmune tis-
ue) and PD-L2 (expressed on APCs). PD-L1 can be upregulated by
oth IFN/ and IFN , leading to a high expression in a variety
f inﬂamed tissues, tumors as well as TILs [35]. PD-L1 exerts its
unction by binding to PD-1 and B7.1 (CD80), both of which are neg-
tive regulators of T cell activation signaling, thereby suppressing
 cell migration, proliferation and secretion of cytotoxic mediators
32,36]. Treatment with the humanized antibody MPDL3280A in
 small percentage of patients with high levels of PD-L1 appears
ost effective due to the re-invigoration of pre-existing immunity
y tumor antigen-speciﬁc TILs [32]. Finally, combination therapies
ay  overcome the limitations of anti-CTLA-4 and anti-PD-1/PD-
1 monotherapies: In fact, anti-CTLA-4 apparently drives T cells
owards the tumor site, resulting in increased numbers of T cells
nd an increase in IFN levels. This, in turn, induces expression
f PD-L1 in the tumor microenvironment, subsequently inhibiting
ntitumor T cell responses. However, it also increases the chance
f clinical beneﬁt from anti-PD-1 or anti-PD-L1 therapy regimens
n these patients. Combination therapies thus in deed appear to
nduce a superior immunogenic tumor microenvironment with
igher clinical beneﬁt [37].
Adoptive T cell therapy (ACT) relies on the in vitro expansion
f endogenous, cancer reactive T cells (mainly CD8+ cytotoxic T
ells), which are harvested from cancer patients, manipulated, and
hen reintroduced as a mechanism for generating productive tumor
mmunity [12]. ACT using ex vivo expanded T cells can induce
umor regression in patients with advanced melanoma [38]. T cells
ransduced with tumor antigen-speciﬁc T cell receptor transgenes
ave been used to treat patients with melanoma [39] or B cell
ymphoma [40], thereby bypassing the need to expand tumor-
peciﬁc T cells ex vivo. Nevertheless, the therapeutic efﬁcacy of ACT
ppears to be limited by immunosuppressive mechanisms within
he tumor-bearing host. While tumor-speciﬁc immune responses
re frequently observed, sustained clinical beneﬁts are documented
n only a small fraction of patients [12]. In line with ACTs, a new type
f immunotherapy, known as chimeric antigen receptor (CAR)-
odiﬁed T cell therapy, has recently emerged. T cells are removed
rom the patient’s blood and genetically altered to have speciﬁcetters 178 (2016) 31–36 33
antigen receptors that are speciﬁc to tumor antigens on the surface
of cancer cells. Such genetically modiﬁed T cells are expanded and
infused back into the patient’s blood, where they induce a targeted
immune attack against the cancer cells. CAR T cell therapy for ALL
(Acute lymphoblastic leukemia) combines chemotherapy with ex
vivo reprograming of previously removed T cells, genetically trans-
duced with a CD19 antigen-speciﬁc CAR. The therapy is the ﬁrst
effective treatment for relapsed ALL patients in adults and children,
where up to 88% of the patients achieved remission [21,41].
4. Beyond current cancer immune therapy regimens
Nuclear receptors (NRs) are transcription factors that have been
shown to be essential for both pro- and anti-inﬂammatory T cell
responses. NRs directly bind DNA and regulate gene expression
in response to ligands. NRs can transduce signals from glucocor-
ticoids, mineralocorticoids, sex steroids (estrogen, progesterone,
and androgen), thyroid hormones, or vitamins either as homo-
or heterodimer. All of the NRs have common structural features,
which include a central DNA-binding domain (DBD) responsi-
ble for targeting the receptor to highly speciﬁc DNA sequences,
a ligand-binding domain (LBD), which recognizes speciﬁc lig-
ands, a functional transactivation site (AF-1) for gene regulation,
a ligand inducible activation function (AF-2) for co-activator and
co-repressor interactions, and a hinge region, connecting the DBD
with the LBD inﬂuencing intracellular trafﬁcking and subcellular
distribution [42,43]. Increasing evidence shows that perturbations
of NR signaling pathways engaged downstream of the TCR underlie
the development of several immune pathologies including cancer.
We discovered the orphan nuclear receptor subfamily 2, group
F, member 6 (NR2F6) to act as a direct signaling intermediate
and threshold regulator of TCR/CD28-mediated signal transduc-
tion in primary mouse and human CD3+ T cells. NR2F6 is termed
orphan nuclear receptor because endogenous ligands are unde-
ﬁned [44]. NR2F6 thereby functions as a critical protein kinase
C (PKC) effector substrate and essential non-redundant nega-
tive regulator of adaptive immunity [45,46]. NR2F6 represents
a widely expressed transcription factor and is a member of the
COUP-TF (chicken ovalbumin upstream promoter transcription
factor) family. This COUP-TF family of NRs has two  other mam-
malian family members, NR2F1 (COUP-TFI) and NR2F2 (COUP-TFII).
COUP-TF family members as homo- or hetero-dimers are pre-
bound to cognate DNA response elements, i.e. AGGTCA direct or
inverted repeats with various spacing and are thought to act as
a repressor for locking out stochastic transcriptional activation of
pro-inﬂammatory cytokine genes. In transfected cell line studies,
the role of NR2F6 was  ﬁrst described in 2003 by Liu et al., refer-
ring to an inhibitory effect of EAR2/NR2F6 on renin transcription
[47,48]. Of note, NR2F6 was reported to be overexpressed in col-
orectal cancer biopsies [49]. Warnecke et al. described the ﬁrst
Nr2f6 knockout mouse in the context of brain development in
2005. Mice were born alive and fertile but lacked <70% of the locus
coeruleus leading to a mildly altered circadian behavior demon-
strated by delayed entrainment to shifted light-dark cycles, less
adaption to daytime feeding schedules, and increased pain sensi-
tivity [50]. Of note, Ichim et al. describe a candidate regulatory role
of NR2F6 during T cell development. Bone marrow reconstitution
experiments with forced overexpression of recombinant NR2F6
resulted in limited T cell development and decrease in thymus
size and cellularity [51]. Our investigations with Nr2f6 knockout
and transgenic overexpression in mice, however, excluded any
defect in thymus development (unpublished data). Importantly,
however, the NR2F6-dependent transrepression pathway(s) of pro-
inﬂammatory cytokines in particular appear(s) to play a key role in
local and systemic inﬂammation.
34 V. Klepsch et al. / Immunology Letters 178 (2016) 31–36
Fig. 1. The two scenarios of cancer immunity: During effective tumor immune surveillance, innate and adaptive immune cells eradicate the developing tumor within the
tumor  microenvironment. If this process is not successful, tumor immune evasion occurs and tumors form metastases and become clinically relevant. In deed, certain types
of  cancer, namely melanoma and lung cancers have been deﬁned as immunogenic diseases. Thus, the concept of targeting immune cells rather than cancer cells in order to
shrink tumors is currently being successfully translated into the clinic via blockade of immune checkpoints such as CTLA-4 and PD-1 leading to prolonged survival of a small
percentage of patients. Orphan nuclear receptor NR2F6 appears to be an alternative immune checkpoint, directly repressing antitumor transcriptional programs within T
cells,  subsequently contributing to an immune suppressed state of effector T cells within the tumor microenvironment. Our preclinical data validate NR2F6 as an innovative
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n  theory, implies full druggability of NR2F6 for a “small molecule checkpoint block
. Biological relevance of NR2F6 in the regulation of T
ell-mediated immune responses
NR2F6 has a critical regulatory function in the adaptive immune
ystem [45], as it negatively controls T cell receptor/CD28-mediated
ransactivation of key transcription factors such as nuclear factor
f activated T cells (NFAT) and the activating protein 1 (AP-1). We
bserved that during TCR activation, a PKC/NR2F6 module and a
egulatory phosphorylation on the NR2F6 DBD function as a critical
eedback mechanism [45]. Upon high afﬁnity antigen receptor sig-
aling, PKC-mediated phosphorylation of Ser-83 within the DBD of
R2F6 abrogates the DNA-binding capacity of NR2F6, thereby pro-
oting unopposed DNA binding of NFAT/AP-1 transcription factors
t the critical cytokine gene loci [45,46]. Our most recent research
onﬁrms the T cell-intrinsic “NR2F6 restraint mechanism” to be
n control of the initiation, magnitude and duration of IL-2, IFN
nd TNF cytokine gene expression of effector T cells in vitro and
n vivo [52]. Collectively, these ﬁndings support the concept that the
ntegrity of a PKC/NR2F6 signaling complex is mandatory for proper cell effector functions and ﬁne-tuning of an adaptive immune
ontexture favoring continuous tumor cell elimination.
Mechanistically, NR2F6 acts as transcriptional repressor in TH0
nd TH17 cells via direct binding to the Il2 and Il17a promoter loci,ation of NR2F6 in T cells could represent a compelling immune therapeutic strategy
, Importantly, the evolutionarily conserved ligand binding domain (LBD) of NR2F6,
rug” for the treatment of cancer.
thus suppressing DNA accessibility of NFAT and AP-1 at this pro-
moter site. NR2F6 facilitates repression of cytokine production also
in TH1 CD4+ as well as CD8+ effector T cells, thereby affecting T cell
activation and effector outcomes. In the experimental autoimmune
encephalomyelitis (EAE) model, Nr2f6-deﬁcient mice displayed sig-
niﬁcantly augmented disease progression [45], validating in vivo an
involvement of NR2F6 in induction and/or maintenance of autoim-
munity. The exact molecular pathway by which NR2F6 impairs
the transcriptional amplitude of NFAT/AP-1 gene transactivation
including all target genes of NR2F6 is currently under investigation.
Longstanding evidence, however, suggests that activated NFAT
proteins must exceed a certain threshold level before they can initi-
ate transcription [53]. Because NFAT proteins are master regulators
of T cell-derived cytokine transcription, it makes sense for NFAT to
function within a negative feedback loop that is capable of down-
modulating immune responses by inducing and/or maintaining an
anergic state. Importantly, NFAT2 is expressed at only low levels
in resting T cells, but is markedly induced upon T cell activation,
to augment and sustain NFAT-regulated gene transcription, which
is important for the development and function of effector T cells.
The induction of NFAT2 upon T cell activation is mediated primar-
ily by constitutively expressed NFAT1 [54,55]. Along these lines,
transcription factor (TFs) proteins are well established to directly
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ompete with other TFs to regulate promoter transcription by shift-
ng the stoichiometric balance of promoter occupancy. Thus, in
his model, NR2F6 expression levels may  signiﬁcantly affect the
hreshold level of DNA-bound NFAT proteins on key promoter loci
hat are required to increase NFAT-driven gene transcription and
revent peripheral tolerance. Furthermore, NR2F6 thereby could
irectly antagonize NFAT1- and NFAT2- modulated transcription
55]. By simultaneously inhibiting Nfat2 transcription directly via
ts NFAT1-mediated promoter activation in a feed-forward loop,
R2F6 might be able to govern cytokine expression. In this model
f T cell physiology, based on its ability to inhibit NFAT1-mediated
ranscription, NR2F6 would be able to intervene at two  levels. First,
R2F6 modulates initial NFAT1-mediated immune responses by
inding to cytokine promoters directly antagonizing NFAT1, where
t is thought to actively suppress transcription [45,46]. Second, and
s a direct consequence, the second wave of NFAT activation might
e suppressed by inhibiting the upregulation of NFAT2 in response
o T cell activation, thereby maintaining the level of activated NFAT
roteins below that required for transcriptional activation. The
brogation of NFAT1 binding in the presence of NR2F6 would serve
s a feed-forward mechanism that could suppress the activation-
nduced expression of Nfat2 mRNA and protein in T cells. Similarly
o the Il2 and Il17a promoters, candidate NFAT/NR2F6 combi-sites,
s deﬁned by computer analysis in silico, where NR2F6 was found to
ind to DNA immediately adjacent to NFAT, are located in the Nfat2
romoter locus. NR2F6 may  therefore augment its effect on NFAT-
riven promoters by limiting the amount of de novo expressed
FAT2 that is available, thereby maintaining its levels below the
hreshold required for transcriptional activation, which is espe-
ially important in T cell effector function [46]. Of note, this is also
xpected to affect tolerance induction during suboptimal TCR stim-
lation conditions. Indeed, primary T cells that are derived from
r2f6-deﬁcient T cells did not respond to induction of classical
nergy by the Ca2+ ionophore ionomycin and are signiﬁcantly less
ensitive to activation-induced cell death (AICD) that is induced by
D3 stimulation in vitro ([45] and unpublished results).
Of note, NR2F6 is strongly upregulated in chronically activated
 cells as an “exhaustion factor”, further strengthening its impor-
ant negative regulatory function in adaptive immunity. Nothing,
owever, was  known about a negative regulatory role of NR2F6 in
ther T cell-mediated immune diseases such as cancer. We  have
ow identiﬁed NR2F6 to be pre-bound to its hormone response
lements (HRE) on deﬁned gene loci in steady state. Investigat-
ng NR2F6 in CD3+ T cell biology helped deﬁne its role in tumor
mmunity in various mouse cancer models. Analysis of the molec-
lar mechanism underlying NR2F6 function revealed a T effector
ell intrinsic role of NR2F6, repressing tumor rejection by reducing
umor T cell inﬁltration as well as cytokine production at the tumor
ite [52]. Employing Nr2f6-deﬁcient mice and T cells to investigate
he effect of NR2F6 on the growth of endogenous and transplanted
umors, we were able to demonstrate that the absence of NR2F6
n T cells leads to a drastic increase in the inﬁltration of various
umors by immune cells, speciﬁcally T cells, showing an overacti-
ated phenotype with increased secretion of IL-2, IFN and TNF
s key effector cytokines by both TH1 CD4+ and CD8+ effector T
ells. As a consequence of increased immune cell inﬁltration and
ctivation, Nr2f6-deﬁcient tumor-bearing mice show signiﬁcantly
educed tumor growth due to their hyperactive cancer immunity.
hus, this study identiﬁes NR2F6 as a critical negative regulator
f T cell immune responses and inhibition of NR2F6 as a poten-
ial cancer therapeutic target in the clinic for enhancing antitumor
mmune responses (Fig. 1).Albeit nuclear receptors directly regulate gene expression in
esponse to lipophilic ligands, nearly half of all human NRs includ-
ng NR2F6 lack valid information on endogenous ligands. Because
utations designed to reduce the size of the evolutionarily con-
[etters 178 (2016) 31–36 35
served LBD pocket or to disrupt co-repressor interactions has
been shown to signiﬁcantly reduced NR2F6 transrepression activ-
ity [46], the LBD of NR2F6 appears essential for its transcriptional
repressor activity. This biochemical evidence strongly suggests
that endogenous NR2F6 ligands, although currently undeﬁned,
may  exist and presumably modulate the active conformation to
induce homo- and/or hetero-dimerization and/or recruitment of
co-activators/co-repressors. As an approach towards this goal,
afﬁnity chromatography of cellular lipidomes with the NR2F6 LBD
and subsequent functional assays are currently performed in order
to deﬁne candidate ligands of NR2F6. If successful, its endogenous
ligands will help to resolve the regulation mechanisms for the LBD
of NR2F6. Furthermore, a deﬁned NR2F6-ligand interaction would
provide valuable proof-of-principle of NR2F6 druggability that will
aid in the development of a “small molecule checkpoint blockade
drug” for immunomodulation in the clinic.
In conclusion and because there is a high scientiﬁc interest to
explore novel cancer immune-therapeutic avenues with the ulti-
mate goal to strengthen the patient’s immune system for a longer
progression-free survival, our validation of a both alternative and
potentially druggable immune checkpoint may extend the beneﬁts
of clinical treatment in the future.
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